

This material is an English translation of the press release announced on Mar. 11, 2024 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Mar. 11, 2024

Notification of Completion of Construction of the New Research Laboratory “SAGA Global Research Center”

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide; hereinafter “Hisamitsu Pharmaceutical”) announced today that it has decided to name a new research laboratory as “SAGA Global Research Center” that was constructed in own business site located in Himekata-Machi, Tosu City, Saga Prefecture, and held a completion ceremony for the construction on March 9, 2024.

[SAGA Global Research Center]



In February 2022, Hisamitsu Pharmaceutical started its “7th Medium-Term Management Policy from the fiscal year ending February 2022 (FY2021), and based on the new company mission: “Promoting TE-A-TE Culture Worldwide”, we are developing our corporate activities to contribute to improving quality of life of people around the world through a variety of products and services. In order to further strengthen our R&D capabilities, we have been considering the reconstruction of our research structure.

In the reconstruction of this research structure, the research functions that were located at two sites in Tosu City, Saga Prefecture and Tsukuba City, Ibaraki Prefecture, was consolidated into one site, and the speed of development will be improved by maximizing collaboration among researchers

and R&D functions, and collaboration between R&D and production division will be strengthened. The new research laboratory we have constructed this time was named “SAGA Global Research Center” with the intention of becoming a technological site that will create new “TE-A-TE treatments” worldwide from Saga prefecture where our business were founded.

SAGA Global Research Center will also have a collaborative experimental space, and in order to create new innovations by building networks with universities and research institutions in Japan and oversea countries to promote open innovations based on TDDS (Transdermal Drug Delivery System), which will lead to the creation of new “TE-A-TE treatments”.

[Innovation Nexus Office]



The office space is named “Innovation Nexus Office” with the hope that innovative ideas and concepts will intersect and that it will become a center where induce new innovations. The office space is also designed to facilitate communications among researchers.

In addition, SAGA Global Research Center is designed with environmental friendly considerations, including measures to conserve energy and reduce emissions of CO₂, and has obtained ZEB Ready certification for its BELS evaluation.

Since its inception in Tashiro, Tosu City, Saga Prefecture in 1847 (at that time in Hizen-Tashiro), Hisamitsu Pharmaceutical has been based in this area, delivering products to the entire country of Japan and to countries around the world, based on the concept of "The Customer-first Principle." Hisamitsu Pharmaceutical will continue to contribute to improving quality of life of people around the world by accelerating R&D activities through this new research organization at the place of its establishment and delivering a variety of products to global customers at the earliest.

[Overview]

Name: SAGA Global Research Center

Address: 370-1, Yomesaka, Himekata-Machi, Tosu, Saga

Building area: 5,660m²

Total floor area: 23,290m²

Start of Constructions: September 28, 2022

Completion of Constructions: February 29, 2024

[At the Completion Ceremony]



(Photo from left)

Mr. YAMAGUCHI, Yoshinori: Governor of Saga Prefecture

Mr. NAKATOMI, Kazuhide: President and CEO, Hisamitsu Pharmaceutical Co., Inc.

Mr. MUKAIKADO, Yoshihito: Mayor of Tosu City